Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
4Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Shattuck Labs, Inc. (STTK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
5High confidence
0.787Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Shattuck Labs, Inc. Suppliers
Ticker
Name
Confidence
Evidence
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
92%
The Company entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s …
Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, bot…
Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
Shattuck Labs, Inc. Customers
Ticker
Name
Confidence
Evidence
KAYAK-THERAPEUTICS-INC
KAYAK-THERAPEUTICS-INC
85%
ffects of this economic instability on our future operations. Components of our Results of Operations Related Party License Revenue Revenue recognized in 2025 was a result of an exclusive license agr…
Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
r development costs than those in later stages of development. In 2026, we anticipate initiating Phase 2 clinical trial(s) for SL-325. Accordingly, we expect an increase in research and development a…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
r development costs than those in later stages of development. In 2026, we anticipate initiating Phase 2 clinical trial(s) for SL-325. Accordingly, we expect an increase in research and development a…
Shattuck Labs, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
STTK-DEBT-12807
Warrants outstanding: 40511011
90%
xbrl warrant detail from xbrl 2025-12-31.
STTK-DEBT
Debt stack $2.9M
90%
Market cache reports total debt of $2.9M.
Shattuck Labs, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Shattuck Labs, Inc..
Shattuck Labs, Inc. Ownership
Holder
Name
Confidence
Evidence
STTK-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME
T. Rowe Price Investment Management, Inc.
90%
13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 84 tracked holders.
